(Q82270514)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

main subject

phase II clinical trial

1 reference

2

Mark J Ratain

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Simon Pacey

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Keith T Flaherty

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Stanley B Kaye

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Lisa Cupit

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Eric K Rowinsky

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Chenghua Xia

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Peter J O'Dwyer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

I R Judson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

18 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

481-488

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20016927%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-009-9367-9

15 January 2020

exact match

0 references

cites work

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

12 December 2020

Targeted therapies for soft-tissue sarcomas

1 reference

12 December 2020

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

1 reference

12 December 2020

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

12 December 2020

Mutations of the BRAF gene in human cancer

1 reference

12 December 2020

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

12 December 2020

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Sorafenib in advanced hepatocellular carcinoma

1 reference

12 December 2020

Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

12 December 2020

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

ras oncogenes in human cancer: a review

1 reference

12 December 2020

BAY 43-9006: preclinical data

1 reference

12 December 2020

Novel treatment strategies for soft tissue sarcoma

1 reference

12 December 2020

Should patients with advanced sarcomas be treated with chemotherapy?

1 reference

12 December 2020

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

12 December 2020

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor

1 reference

12 December 2020

Epidemiology of soft tissue sarcomas in adults

1 reference

12 December 2020

Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants

1 reference

12 December 2020

Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas

1 reference

12 December 2020

C-kit, GIST, and imatinib.

1 reference

12 December 2020